2026-04-14T06:10:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:10854/44182024-12-13T11:01:24Zcom_2072_212938com_2072_106col_2072_212944

A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART Gómez, Carmen E. Perdiguero, Beatriz García Arriaza, Juan Cepeda, Victoria Sánchez-Sorzano, Carlos Óscar Mothe, B. Jiménez, José Luis Muñoz Fernández, María Ángeles Gatell, J.M. López Bernaldo de Quirós, Juan Carlos Brander, Christian Garcia, Felipe Esteban, Mariano Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades Sida -- Tractament VIH (Virus) info:eu-repo/semantics/article info:eu-repo/publishedVersion Elena Gomez, C., Perdiguero, B., Garcia-Arriaza, J., Cepeda, V., Oscar Sanchez-Sorzano, C., Mothe, B., et al. (2015). A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART. PLoS One, 10(11), e0141456 1932-6203 http://hdl.handle.net/10854/4418 https://doi.org/10.1371/journal.pone.0141456 http://hdl.handle.net/10854/4418 eng Aquest document està subjecte a aquesta llicència Creative Commons http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess application/pdf Plos One